Study identifier:18-513
ClinicalTrials.gov identifier:NCT03661528
EudraCT identifier:2018-002620-17
CTIS identifier:N/A
A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor
Acute Intracranial Hemorrhage
Phase 4
No
andexanet alfa, Usual Care
All
530
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Dec 2025 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: andexanet alfa Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose. | Drug: andexanet alfa Andexanet alfa is a recombinant version of human FXa |
| Other: Usual Care Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate. | Drug: Usual Care Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate. |